Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

Teruo Jojima(Dokkyo Medical University), Yoshimasa Aso(Dokkyo Medical University)

Diabetology & Metabolic Syndrome

July 25, 2016

10.1186/s13098-016-0169-x

Cited by 199

Related Papers

No related papers found

Powered by citation graph analysis